217 related articles for article (PubMed ID: 16631457)
1. The role of bisphosphonates in preventing skeletal complications of hormonal therapy.
Gilbert SM; McKiernan JM
Urol Clin North Am; 2006 May; 33(2):191-9, vi. PubMed ID: 16631457
[TBL] [Abstract][Full Text] [Related]
2. Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates.
Polascik TJ
Prostate Cancer Prostatic Dis; 2008; 11(1):13-9. PubMed ID: 17923854
[TBL] [Abstract][Full Text] [Related]
3. Bone health in men receiving androgen deprivation therapy for prostate cancer.
Eastham JA
J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
[TBL] [Abstract][Full Text] [Related]
4. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
Kawahara T; Kobayashi T; Nishizawa K; Kobori G; Mitsumori K; Ogura K
Hinyokika Kiyo; 2008 Apr; 54(4):261-6. PubMed ID: 18516917
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
6. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
Smith MR
Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
[TBL] [Abstract][Full Text] [Related]
7. Cancer treatment-induced bone loss in breast and prostate cancer.
Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
[No Abstract] [Full Text] [Related]
9. [Bone and Men's Health. Hormonal therapy and bone loss in prostate cancer].
Izumi K; Mizokami A; Namiki M
Clin Calcium; 2010 Feb; 20(2):175-81. PubMed ID: 20118508
[TBL] [Abstract][Full Text] [Related]
10. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
11. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
Saad F; Abrahamsson PA; Miller K
BJU Int; 2009 Dec; 104(11):1573-9. PubMed ID: 20053188
[TBL] [Abstract][Full Text] [Related]
12. Bone health in men with prostate cancer: diagnostic and therapeutic considerations.
Saad F; Perrotte P; Bénard F; McCormack M; Karakiewicz PI
Can J Urol; 2005 Jun; 12 Suppl 2():9-15. PubMed ID: 16018826
[TBL] [Abstract][Full Text] [Related]
13. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
Israeli RS; Ryan CW; Jung LL
J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
[TBL] [Abstract][Full Text] [Related]
14. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
Ross RW; Small EJ
J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
[TBL] [Abstract][Full Text] [Related]
15. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy.
Bruder JM; Ma JZ; Wing N; Basler J; Katselnik D
J Clin Densitom; 2006; 9(4):431-7. PubMed ID: 17097529
[TBL] [Abstract][Full Text] [Related]
16. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
[TBL] [Abstract][Full Text] [Related]
17. Preservation of bone health in prostate cancer.
Lattouf JB; Saad F
Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
[TBL] [Abstract][Full Text] [Related]
18. Nursing implications of androgen deprivation therapy-associated bone loss.
Weingard KK
Urol Nurs; 2006 Aug; 26(4):261-9; quiz 270. PubMed ID: 16939043
[TBL] [Abstract][Full Text] [Related]
19. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
20. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
